You are making some solid points.
Part of my problem is that I really like Chris Sale, in spite of all his injuries and the wasted dough. Another part is that I really did think we were going hard for the playoffs this year. I'm biased for those reasons, I freely admit it.
I don't blame you. I like Sale, too, and I also expected him to be healthy — and if healthy, quite good.
(I don't get the people who don't like Sale. He had a 7.6 fWAR season as a starter for us
in a year where we won a title. That's the eleventh best fWAR mark for a pitching season for the Red Sox after two of Pedro's, four of Clemens', and four of Cy Young's seasons, tied with another Clemens season and Smoky Joe Wood's 1912 — the only other such season in a WS-winning year. Was he hurt a lot? Sure; it happens — Wood was hurt '13–'15. Was the extension ill advised? Yeah; take that up with Dombrowski. But this franchise is old and accomplished, and he's one of the very best who has ever pitched here.)
I also liked and like the trade. Chris Sale is 35 years old, and that means he just isn't a good fit for a team whose window is opening — like ours is. That doesn't mean we're not trying to compete! We
are trying to compete this season; indeed, we are competing — we're tied with Detroit and Texas with the best record of a team not presently in a wild card spot. But I think it's fair to say we should be in a position to compete with a higher probability of success in the coming seasons.
Even if he's healthy and performs, a guy like Sale imposes a tradeoff on a roster like ours: playing time we give him isn't playing time we're using to identify future rotation mainstays. This winter, people here wanted Houck (controllable through 2028) in the pen because he couldn't face a lineup three times. People here still want Whitlock (2027) in the pen. By the end of this season, both of those guys, along with Crawford (2029) and Bello (2030) will look like the anchors of our rotation.
Sale might well be very good this year, but it's pretty unlikely that he'll be good throughout what we're hoping is a five-year window of serious contention. Swapping him out for a potential infield piece in Grissom (who's period of team control
does lineup with that window) and making space to sign a 29-year-old Lucas Giolito helps that — or would have helped if Giolito hadn't gotten hurt. The point is, dealing Sale gave us a rotation slot to offer to a younger FA. The projected step down from Sale to Younger FA Pitcher was less — even for 2024 — than the projected step up from last year's catastrophic 2B situation to Grissom. In hindsight, we should have beaten the Cubs' offer for Shota Imanaga instead of signing Giolito, but Giolito's youth shouldn't be understated. If Breslow and Bailey
had gotten Giolito back on track — and given what they're getting out of Cooper Criswell (controllable until the heat death of the universe)
, that is not at all hard to believe — we'd likely be extending him for a half-decade at the All Star Break.
On the Braves' side — while Strider's injury changes things; they are relying much more on Sale than I think they would have anticipated — Sale should be a
luxury for the Braves, so his age and injury risks aren't as big a deal for them; I think they can make the playoffs with or without him. They traded us Grissom for a 50% chance of having Chris Sale start an NLCS game against the Dodgers, and that was probably a smart move.